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Dermoscopy to Monitor the Therapeutic Response 
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 a   Department of Dermatology, Ospedale Regionale Bellinzona e Valli,  Bellinzona , and  b   Institute of Pathology, 
 Locarno , Switzerland 
surface scaling or crusting that may erode  [1, 2] . Dermos-
copy is considered a useful method for the diagnosis of 
BD based on the typical glomerular vessels plus scaly sur-
face and also for monitoring the therapeutic response of 
BD  [3, 4] . The therapeutic approach for BD includes ob-
servation alone and topical and surgical treatments  [1, 2] .
 Ingenol mebutate (IM) is a topical drug recently avail-
able for the treatment of actinic keratoses (AK) and was ap-
proved in Switzerland in June 2013 for this indication  [5] . 
The advantage of IM compared with other topical agents 
for AK therapy appears to be its dual mechanism of action – 
a rapid necrosis after only 2 or 3 days’ application of IM gel 
and the subsequent immune-mediated response – which 
targets any residual dysplastic epidermal cells  [6, 7] .
 We report the case of a 73-year-old woman with non-
pigmented BD on her right forefinger, for which we had 
tried several local and surgical treatments, which had all 
led to recurrence of the tumour. A local therapy with IM 
led to a lasting remission of BD.
 Case Report 
 We report the case of a 73-year-old woman with skin phototype 
III and with a history of a myeloproliferative syndrome positive for 
a JAK2V617F mutation and osteomyelofibrosis, which had oc-
curred 17 years ago. She was treated with oral thioguanine and sple-
nectomy at first. Eight years after the initial diagnosis, an alloge-
neic HLA-identical stem cell transplant was performed. During the 
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 Abstract 
 Ingenol mebutate (IM) has recently been approved for the 
topical treatment of actinic keratoses. It appears to have a 
dual mechanism of action: rapid necrosis after gel applica-
tion and a subsequent immune-mediated response, which 
targets any residual dysplastic epidermal cells. We report the 
successful treatment of a woman, who had been relapsing 
into Bowen’s disease (BD) on her right forefinger for 8 years. 
During her clinical history, she had received an allogeneic, 
HLA-identical stem cell transplant for myeloproliferative 
syndrome with a JAK2V617F mutation and lobectomy of the 
pulmonary right lower lobe for adenocarcinoma. We used 
dermoscopy to monitor the therapeutic response of BD. We 
discuss IM gel as a possible therapeutic option for BD. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Bowen’s disease (BD) is a form of in-situ squamous 
cell carcinoma (SCC). The typical cutaneous non-pig-
mented BD presents as a slowly growing, well-demarcat-
ed erythematous plaque, with an irregular border and 
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2 years after the bone marrow transplant, the patient benefitted 
from immunosuppressive therapy with oral cyclosporine A. In the 
following years, she no longer needed any treatment for her hema-
tological disease and did not experience relapse throughout this pe-
riod. The patient’s state of health was satisfactory except that 7 years 
after the bone marrow transplant she developed an adenocarcino-
ma of the right lung lower lobe (stage γpT3 γpNO MO), which was 
successfully removed by right lower pulmonary lobectomy.
 One year after stem cell transplant and 9 years after the initial 
diagnosis, she slowly developed an erythematous plaque on her 
right forefinger. A skin biopsy was performed and the histological 
diagnosis was BD. A 5-fluorouracil (5-FU) 5% cream applied twice 
daily for 3 weeks led to remission of BD, but less than a year later, 
she relapsed. During the following years, BD was treated with dif-
ferent modalities alternating between 5-FU and imiquimod (IQ) 
5% gel, always relapsing a few months after every treatment cycle. 
This cycle of remission and relapse continued after cyclosporine A 
had been stopped as well.
 We examined the patient for the first time 15 years after the first 
diagnosis of myeloproliferative syndrome and 6 years after the stem 
cell transplant. On the distal medial aspect of her right forefinger, she 
presented an erythematous plaque that overflowed above the line of 
Wallace measuring 15 × 12 mm ( fig. 1 a). We performed a shave bi-
opsy in truncal anesthesia. The histological examination confirmed 
the diagnosis of BD showing full thickness, markedly atypical and 
dyskeratotic cells of epidermis with mitoses and parakeratosis 
( fig. 1 b–d). Afterward, the patient was treated by a methyl aminolae-
vulinate (MAL) – photodynamic therapy (PDT). BD relapsed at the 
lesion edges after 6 months. We therefore treated with IQ 5% cream 
for 1 month, but BD recurred again 6 months thereafter. One year 
after the first MAL-PDT, it was treated for a second time.
 After a year’s relapse of BD at the edges ( fig. 2 a, b), we decided to 
perform an off-label treatment with IM 500 μg/g gel, administered 
once daily for 2 consecutive days, following the clinical course with 
dermoscopy. At that moment, a treatment with 5-FU 5% cream was 
refused by the patient, because she complained of pain during previ-
ous therapies. Three days after the first application of IM, the skin 
lesions occurred more reddening and vesicular ( fig. 2 c). At the der-
moscopy examination, the typical glomerular vessels had disap-
peared, leaving room for an apple juice-like colored picture without 
vascular structures ( fig. 2 d). But after 6 weeks, the clinical appearance 
seemed to have reverted to the same state as before the treatment, 
which was also confirmed by a dermoscopy where glomerular vessels 
in the lesion reappeared ( fig. 3 a, b). With the informed consent of the 
patient, we decided to treat her with IM 500 μg/g gel, administered 
once daily for 1 day under occlusion of a patch. The patient com-
plained of pain and a burning sensation a few hours after application 
of IM. We treated with oral paracetamol 3 times 1 g daily. Following 
the removal of the patch after 24 h, the symptoms disappeared grad-
ually after 2 days. Three days after the application of IM, vesicular and 
dyshidrotic skin lesions occurred ( fig. 3 c). On dermoscopy, the le-
sions showed a scaly and hyperkeratotic picture with disappearance 
of the glomerular vessels ( fig. 3 d). At 6 weeks follow-up, we found 
clinical remission ( fig. 4 a) without glomerular vessels on dermoscopy 
( fig. 4 b). Follow-up at 3 months confirmed clinical and dermoscopi-
cal remission ( fig. 4 c, d). At 6 months’ follow-up after the second 
treatment with IM, there had been no relapse with excellent cosmesis.
 Discussion 
 Cutaneous BD is an intra-epidermal skin tumor, pre-
senting as a circumscribed erythematous plaque with 
scaly or crusted surface or as verrucous or pigmented 
a b
dc
 Fig. 1.  a Relapsing BD of the right forefin-
ger 5 years after the first diagnosis;  b shave-
excision with full-thickness atypia of the 
epidermis and parakeratosis. H&E ×100; 
 c   disorderly maturation of the epidermis 
with marked atypia and dyskeratotic cells. 
H&E ×200;  d dyskeratotic cells and mitoses 
at different levels in the epidermis. H&E 
×400. 
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variants. The risk of progression to an invasive SCC is 
small, estimated at 3–5%. Women are most affected (75–
85% of the cases). About 3 quarters of tumors are local-
ized in lower extremities. In 80–90% of the patients, the 
lesion appears solitary. Many etiological factors are dis-
cussed: irradiation (solar, photochemotherapy, radio-
therapy), arsenic, immunosuppressive diseases or treat-
ments, chronic dermatoses or pre-existent skin lesions 
and viral-oncogenic human papilloma virus. About 30–
50% of the subjects, who developed a BD, also develop or 
a b
c d
 Fig. 2.  a Relapsing BD of the right forefin-
ger 8 years after the first diagnosis;  b der-
moscopy of non-pigmented BD showing 
glomerular vessels that are arranged in 
clusters and white to yellow scales;  c after 
3  days’ treatment with IM, moderate-to-
severe reaction is visible with confluent 
dyshidrotic vesicles;  d dermoscopy after 
3 days’ treatment with IM, amorphous ery-
thematous confluent vesicles and white 
scales. 
a b
c d
 Fig. 3.  a Relapsing BD of the right forefin-
ger 6 weeks after the first IM treatment; 
 b   dermoscopy showing a resurgence of 
dotted and glomerular vessels associated 
with marketed white scales;  c after 3 days’ 
treatment with IM, severe reaction is visi-
ble with confluent dyshidrotic vesicles; 
 d  dermoscopy after 3 days’ treatment with 
IM, amorphous erythematous confluent 
vesicles and white scales. 
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have developed a non-melanoma skin cancer, probably 
reflecting common solar damage  [1, 2, 8] .
 The clinical diagnosis of BD is usually confirmed by a 
biopsy, showing full-thickness epidermal dysplasia with-
out dermal invasion  [1, 2, 8] . Micali et al.  [9] reviewed, 
according to evidence-based analysis, therapeutic possi-
bilities for the topical treatment of skin cancers and found 
5-FU, IQ, PDT and surgery with documented efficacy.
 Dermoscopy is used by dermatologists not only as a 
non-invasive method for the diagnosis of skin cancers but 
also to monitor the treatment efficacy in the follow-up. At 
dermoscopy, non-pigmented BD shows a characteristic 
morphologic type of dotted and tortuous vessels similar 
to the glomerular apparatus of the kidneys or arranged in 
lines at the periphery and opaque, yellow to white scales. 
Histopathologically, the glomerular vessels correspond to 
the presence of convolutions of capillaries in the dermal 
papillae, which are grouped in clusters and are dilated  [3, 
4, 10–13] . Mun et al.  [4] proposed an algorithm for the 
clinical use of dermoscopy to monitor the therapeutic re-
sponse of BD: once these vascular structures disappear, 
the BD is clinically cured. The histopathological exami-
nation typically is negative for remains of BD. In these 
cases, the authors suggested a regular follow-up by der-
moscopy. If on dermoscopy the glomerular vessels per-
sist, a histopathological assessment of the skin lesion is 
needed, and in these cases, BD is typically found on his-
tology  [4] .
 In Australia, Ogbourne et al.  [14] first described the 
preclinical activity of IM (PEP005, ingenol-3-angelate), a 
hydrophobic diterpene ester isolated from the plant  Eu-
phorbia peplus , for the treatment of skin cancer. The same 
group demonstrated that IM field-directed treatment of 
UVB-damaged skin reduced tumor lesion formation and 
removed mutant p53 patches  [15] . A recent article eluci-
dated direct effects of IM on primary keratinocytes, pa-
tient-derived SCC cells and a SCC cell line  [16] . IM thus 
inhibits viability and proliferation of all keratinocyte-de-
rived cells in a biphasic way – IM-induced cell death is 
mediated through the PKCδ/MEK/ERK pathway and the 
downstream induction of IL1R2 and IL13RA2 expression 
to the reduced viability of IM-treated cells  [16] . Longo et 
al.  [17] recently reported 2 cases of non-invasive moni-
toring of morphological changes in AK treated with IM 
using a combination of dermoscopy and reflectance con-
focal microscopy. They concluded that both methods 
represent a non-invasive possibility to monitor treatment 
efficacy of this new drug  [17] .
 We describe a case of recurring BD successfully treated 
with IM gel. A first article  [18] reported a case of a 74-year-
old man treated with sunitinib, a multi-kinase inhibitor, 
for metastatic renal cell carcinoma that he had developed 
together with numerous SCC and 2 BD tumors at his ab-
domen. He was treated with IM gel 0.05% once daily for 
2 days consecutively. The healing was confirmed by his-
topathological examination, but was only partial in 1 of 
a b
c d
 Fig. 4.  a The right forefinger 6 weeks after 
the second IM treatment;  b dermoscopy 
not showing a resurgence of dotted and 
glomerular vessels. White scales;  c after 
3  months’ treatment with IM, no BD re-
lapse is visible;  d dermoscopy after 
3 months’ treatment with IM, not showing 
a resurgence of dotted and glomerular ves-
sels. 
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the 2 BD tumors. The authors wrote that a second treat-
ment cycle was planned. A second article  [19] reported a 
case of a 79-year-old woman with BD on the right calf. 
The authors applied IM 0.05% gel on the tumor area once 
daily for 3 days consecutively, achieving a total remission 
after 10 weeks, confirmed by histopathological examina-
tion and without recurrence 6 months after treatment.
 Our patient’s BD had developed when she was still un-
der pharmacological immunosuppression with cyclospo-
rine A. Her immunosuppression may well have been an 
aggravating factor in the numerous recurrences observed. 
As in the first reported case  [18] , remission occurred after 
occlusive use of IM. We thus propose that for recalcitrant 
or relapsing cases of BD, occlusive treatment with IM 
may be a promising approach. Serial dermoscopy proved 
a helpful procedure informing about treatment outcome 
with early detection of relapse at 6 weeks after the first ap-
plication of IM and sparing the patient from additional 
biopsies. We thus believe that dermoscopy is a valuable 
method for the follow-up of topical treatments in BD 
treated with IM  [3, 4, 11–13, 17] .
 Funding 
 This study did not receive funding from third parties. 
Statement of Ethics
Informed consent was obtained from the patient.
 Disclosure Statement 
 C.G. and S.L.-P. declare that they have no conflicts of interest. 
C.M. is member of the Advisory Board Dermatology for LEO 
 Pharma. 
 References 
 1 Cox NH, Eedy DJ, Morton CA; Therapy 
Guidelines and Audit Subcommittee, British 
Association of Dermatologists: Guidelines for 
management of Bowen’s disease: 2006 up-
date. Br J Dermatol 2007; 156: 11–21. 
 2 Morton CA, Birnie AJ, Eedy DJ: British asso-
ciation of dermatologists’ guidelines for the 
management of squamous cell carcinoma in 
situ (Bowen’s disease) 2014. Br J Dermatol 
2014; 170: 245–260. 
 3 Zalaudek I, Argenziano G, Leinweber B, Cita-
rella L, Hofmann-Wellenhof R, Malvehy J, 
Puig S, Pizzichetta MA, Thomas L, Soyer HP, 
Kerl H: Dermoscopy of Bowen’s disease. Br J 
Dermatol 2004; 150: 1112–1116. 
 4 Mun JH, Park JM, Song M, Jwa SW, Kim HS, 
Ko HC, Kim BS, Kim MB: The use of derma-
toscopy to monitor therapeutic response of 
Bowen disease: a dermatoscopic pathological 
study. Br J Dermatol 2012; 167: 1382–1385. 
 5 Hofbauer G, Anliker M, Boehncke WH, 
Brand C, Braun R, Gaide O, Hafner J, Hunger 
R, Itin P, Kaeuper G, Lautenschlager S, 
Mainetti C, Streit M: Swiss clinical practice 
guidelines on field cancerization of the skin. 
Swiss Med Wkly 2014; 144:w14026. 
 6 Rosen RH, Gupta AK, Tyring SK: Dual mech-
anism of action of ingenol mebutate gel for 
topical treatment of actinic keratoses: rapid 
lesion necrosis followed by lesion-specific im-
mune response. J Am Acad Dermatol 2012; 
 66: 486–493. 
 7 Lebwohl M, Swanson N, Anderson LL, Mel-
gaard A, Xu Z, Berman B: Ingenol mebutate 
gel for actinic keratosis. N Engl J Med 2012; 
 366: 1010–1019. 
 8 Morley GL, Matthews JH, Verpetinske I, 
Thom GA: A comparative study examining 
the management of Bowen’s disease in the 
United Kingdom and Australia. Dermatol Res 
Pract 2015; 2015: 421460. 
 9 Micali G, Lacarrubba F, Nasca MR, Ferraro S, 
Schwartz RA: Topical pharmacotherapy for 
skin cancer: part II. Clinical applications. J 
Am Acad Dermatol 2014; 70: 979.e1–e12. 
 10 Argenziano G, Zalaudek I, Corona R, Sera F, 
Cicale L, Petrillo G, Ruocco E, Hofmann-
Wellenhof R, Soyer HP: Vascular structures 
in skin tumors: a dermoscopy study. Arch 
Dermatol 2004; 140: 1485–1489. 
 11 Zalaudek I, Di Stefani A, Argenziano G: The 
specific dermoscopic criteria of Bowen’s dis-
ease. J Eur Acad Dermatol Venereol 2006; 20: 
 361–362. 
 12 Payapvipapong K, Tanaka M: Corona of glo-
merular vessels: a diagnostic marker of hyper-
keratotic Bowen’s disease. Dermatol Surg 
2013; 39: 1395–1398. 
 13 Zalaudek I, Argenziano G: Dermoscopy of ac-
tinic keratosis, intraepidermal carcinoma and 
squamous cell carcinoma. Curr Probl Derma-
tol 2015; 46: 70–76. 
 14 Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, 
Boyle GM, Morris M, McAlpine D, Johns J, 
Scott TM, Sutherland KP, Gardner JM, Le TT, 
Lenarczyk A, Aylward JH, Parsons PG: Antitu-
mor activity of 3-ingenyl angelate: plasma 
membrane and mitochondrial disruption and 
necrotic cell death. Cancer Res 2004; 64: 2833–
2839. 
 15 Cozzi SJ, Ogbourne SM, James C, Rebel HG, 
de Gruijl FR, Ferguson B, Gardner J, Lee TT, 
Larcher T, Suhrbier A: Ingenol mebutate 
field-directed treatment of UVB-damaged 
skin reduces lesion formation and removes 
mutant p53 patches. J Invest Dermatol 2012; 
 132: 1263–1271. 
 16 Freiberger SN, Cheng PF, Iotzova-Weiss G, 
Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer 
R, Skak K, Levesque MP, Hofbauer GF: In-
genol mebutate signals via PKC/MEK/ERK in 
keratinocytes and induces interleukin decoy 
receptors IL1R2 and IL13RA2. Mol Cancer 
Ther 2015; 14: 2132–2142. 
 17 Longo C, Borsari S, Benati E, Moscarella E, 
Alfano R, Argenziano G: Dermoscopy and re-
flectance confocal microscopy for monitoring 
the treatment of actinic keratosis with ingenol 
mebutate gel: report of two cases. Dermatol 
Ther (Heidelb) 2016; 6: 81–87. 
 18 Braun SA, Homey B, Gerber PA: [Successful 
treatment of Bowen disease with ingenol 
mebutate]. Hautarzt 2014; 65: 848–850. 
 19 Lee JH, Lee JH, Bae JM, Kim GM: Successful 
treatment of Bowen’s disease with ingenol meb-
utate 0.05% gel. J Dermatol 2015; 42: 920–921. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
/3
/2
01
7 
1:
02
:0
0 
PM
